Zimmer Biomet (NYSE:ZBH) Given New $130.00 Price Target at UBS Group

Zimmer Biomet (NYSE:ZBH) had its target price boosted by stock analysts at UBS Group from $120.00 to $130.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. UBS Group‘s price target indicates a potential upside of 21.41% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on ZBH. Barclays raised shares of Zimmer Biomet to a “hold” rating in a research note on Wednesday, October 7th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on Zimmer Biomet from $110.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday. Stifel Nicolaus set a $125.00 price target on shares of Zimmer Biomet in a research note on Wednesday. Finally, BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $111.95.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $3.07 during trading hours on Thursday, hitting $107.08. The stock had a trading volume of 3,623,755 shares, compared to its average volume of 2,266,789. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The firm has a 50-day moving average price of $95.01 and a 200 day moving average price of $91.99. Zimmer Biomet has a fifty-two week low of $79.12 and a fifty-two week high of $112.54. The firm has a market capitalization of $20.42 billion, a price-to-earnings ratio of 26.05, a PEG ratio of 2.33 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same quarter last year, the business earned $1.90 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, research analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Activity

In related news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their position. The SEC filing for this sale provides additional information. 1.28% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of the company. Tacita Capital Inc acquired a new position in shares of Zimmer Biomet during the second quarter worth about $26,000. Ancora Advisors LLC purchased a new position in shares of Zimmer Biomet in the second quarter valued at $29,000. Elevation Wealth Partners LLC increased its holdings in Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $44,000. Finally, Parvin Asset Management LLC acquired a new position in shares of Zimmer Biomet in the second quarter worth $47,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, while adjusted EPS of $1.90 topped estimates of $1.88. The company also raised its full-year 2026 outlook; stronger hips and S.E.T. sales helped offset knee-market weakness. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its target to $125 and upgraded ZBH to “outperform,” providing a bullish signal. Royal Bank of Canada recommendations
• Neutral Sentiment: Citigroup lifted its target to $117 but kept a “neutral” rating. Wells Fargo raised its target to $113 and maintained “equal weight.” Citigroup recommendations Wells Fargo recommendations
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS was flat year over year. Knee weakness and margin pressure remain concerns; Bernstein raised its target to $107 but kept a “market perform” rating. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.